Literature DB >> 30281212

Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Martin Stattin1,2, Julia Forster1, Alexandra Graf3, Daniel Ahmed1,2, Ilse Krebs1,2, Siamak Ansari-Shahrezaei1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30281212     DOI： 10.1111/aos.13840

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  3 in total

1.  Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.

Authors:  Martin Stattin; Anna-Maria Haas; Daniel Ahmed; Alexandra Graf; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  Eur J Ophthalmol       Date:  2021-11-02       Impact factor: 1.922

2.  Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration.

Authors:  Martin Stattin; Julia Forster; Daniel Ahmed; Anna-Maria Haas; Alexandra Graf; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  J Ophthalmol       Date:  2020-02-14       Impact factor: 1.909

3.  The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results.

Authors:  Martin Stattin; Daniel Ahmed; Alexandra Graf; Anna-Maria Haas; Stefan Kickinger; Michael Jacob; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  Ophthalmol Ther       Date:  2021-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.